Saffron is derived from the dried stigmas of the crocus flower (Crocus sativus), a sterile, fall-blooming perennial in the Iridaceae family [1][2]. The plant produces vibrant purple flowers from which only the central red stigmas are harvested — entirely by hand, requiring roughly 75,000 to 150,000 flowers per kilogram of spice, making saffron the most expensive culinary ingredient by weight [2][3]. Iran dominates global production, contributing over 85–90% of world supply, with Afghanistan, India (Kashmir), Greece, and Spain also producing notable quantities [2][3].
The bioactive compounds responsible for saffron's therapeutic properties are antioxidant carotenoids and their derivatives. Three principal phytochemicals define the spice: crocins (water-soluble carotenoid glycosides of crocetin, comprising approximately 80% of total pigments and responsible for saffron's deep red-yellow color), picrocrocin (a monoterpene glucoside providing the characteristic bitter taste, present at 2–7% of dry stigma weight), and safranal (a volatile monoterpene aldehyde providing aroma, arising from picrocrocin degradation during drying, present at 0.1–0.6% of dry weight) [1][2][4]. Picrocrocin is considered unique to saffron and is therefore the best authenticity biomarker, since it is not found in common adulterants such as safflower, marigold, or turmeric [5]. Crocins are also found in the fruit of the gardenia plant, but their concentration in saffron is distinctive [6].
Saffron compounds are speculated to exert antidepressant effects by inhibiting the reuptake of dopamine, norepinephrine, and serotonin [7]. Crocin and safranal also demonstrate antioxidant, anti-inflammatory, and neuroprotective activities in preclinical models [8][9]. These mechanisms underpin growing clinical research into saffron supplementation for depression, anxiety, sleep, cognitive decline, and eye health.
The clinical evidence base is characterized by relatively small sample sizes, short trial durations (typically 4–16 weeks), and a high proportion of industry-funded studies. Most early clinical trials were conducted in Iran (the world's largest saffron producer), though more recent investigations from Australia, England, France, Belgium, and Germany have broadened the geographic base of evidence [1][10].
Table of Contents
- Overview
- Forms and Bioavailability
- Evidence for Benefits
- Recommended Dosing
- Safety and Side Effects
- Drug Interactions
- Dietary Sources
- References
Overview
Saffron is derived from the dried stigmas of the crocus flower (Crocus sativus) and contains antioxidant carotenoids, primarily crocins, picrocrocin, and safranal. Crocins provide saffron's characteristic yellow-orange color, picrocrocin its bitter taste, and safranal much of its aroma. Picrocrocin consists of safranal attached to a sugar molecule (45.47% of picrocrocin is safranal) [1].
The amounts of these active compounds vary significantly by geographic location, cultivar, terroir, and post-harvest processing. Picrocrocin is considered unique to saffron and is therefore the best authenticity biomarker [2].
Saffron has been studied primarily for depression, anxiety, sleep, cognitive function, vision, and appetite regulation, with most evidence coming from small, short-term, manufacturer-funded trials. The dried stigmas contain over 150 volatile and non-volatile compounds [2][4], and beyond the three principal bioactives, secondary phytochemicals include other carotenoids (zeaxanthin, lycopene, beta-carotene), flavonoids (kaempferol derivatives), anthocyanins, and various monoterpenes and aldehydes.
Forms and Bioavailability
Whole Saffron vs. Standardized Extracts
Saffron supplements generally do not contain whole saffron powder. Instead, they contain concentrated extracts standardized to specific levels of one or more bioactive compounds [1]. This is an important distinction because the amounts of crocins, picrocrocin, and safranal in whole saffron vary significantly by geographic location, cultivar, and post-harvest processing [1][2].
Branded Standardized Extracts
Saffron supplements typically contain extracts rather than whole saffron powder, standardized to specific concentrations of active compounds:
- Affron — standardized to 3.5% "Lepticrosalides" (reportedly total crocins, picrocrocin, and safranal, measured by HPLC). Used in most depression and sleep studies at 14 mg twice daily (28 mg/day).
- Safr'Inside — standardized to >3% crocins, >0.2% safranal, and >1% picrocrocin derivatives. Used in mood and stress studies at 15 mg twice daily (30 mg/day).
- Satiereal / Supresa — standardized to 0.3% safranal (UV-Vis method). Approximately 6–7 times less concentrated than Affron. Used in appetite studies at 88.25 mg twice daily.
- Saffr'activ — standardized to approximately 6% crocins and 4.5% safranal. Used at 15.5 mg daily in sleep studies.
The relative concentration differences explain dose differences: Affron and Safr'Inside are approximately 6 to 7 times as concentrated as Satiereal, which is why they are effective at substantially lower milligram doses [1].
The UV-Vis vs. HPLC Testing Problem
A critical issue in saffron supplement quality involves how standardized compounds are measured. Many saffron extracts use a spectrophotometric UV-Vis test method that is not specific to the individual compounds claimed on the label. UV-Vis results can vastly overestimate the actual amounts of compounds compared to the more specific HPLC (High Performance Liquid Chromatography) method [1][3].
One study found values for safranal to be 5 to 150 times lower using HPLC compared to UV-Vis, likely because UV-Vis detects a portion of picrocrocin as safranal (since 45.47% of picrocrocin's molecular weight is safranal) [1][3]. This issue has been acknowledged by manufacturers. Inoreal, the French manufacturer of Satiereal/Supresa, acknowledged in correspondence that its safranal standardization represents "the set of compounds that absorb at 330 nm expressed as safranal" rather than the actual percentage of safranal alone [1].
Practical implication: Consumers cannot reliably compare the amounts of specific saffron compounds between products based on label claims alone, because different manufacturers use different analytical methods that yield different results for the same compound.
ISO Quality Grades
Quality grades for whole saffron are defined by ISO 3632, which classifies saffron into three categories based on spectrophotometric thresholds. Category I (highest quality) requires a crocin absorbance of 200 or more (measured at 440 nm), picrocrocin of 70 or more (257 nm), and safranal in the range of 20–50 (330 nm) [2][13]. Studies suggest only about 40% of commercial saffron samples meet ISO Category I purity standards — saffron's high cost makes it a frequent target for adulteration with safflower, marigold, turmeric, synthetic dyes, and food colorants [2].
Solubility and Absorption
Saffron's bioactive compounds have different solubility profiles that affect absorption:
- Crocins are water-soluble carotenoid glycosides. They do not require dietary fat for absorption and can be taken without meals [1].
- Safranal is fat-soluble. To maximize safranal absorption, saffron supplements should be taken around the time of a meal containing fats or oils [1].
- Crocetin, the aglycone backbone of crocins, is lipophilic. Crocins are converted to crocetin in the gastrointestinal tract, and crocetin is the form that reaches systemic circulation [4][12].
Evidence for Benefits
Depression and Anxiety
Depression is the most extensively studied indication for saffron supplementation. Several clinical studies suggest modest benefits, with saffron compounds speculated to work by inhibiting the reuptake of dopamine, norepinephrine, and serotonin [4].
Meta-analytic evidence: A meta-analysis by Hausenblas et al. (2013) concluded that saffron supplementation significantly improved symptoms of depression compared to placebo, with effect sizes suggesting clinical relevance in mild-to-moderate depression [14]. Subsequent meta-analyses from 2020 onward affirm saffron's antidepressant effects surpass placebo, potentially through serotonin reuptake inhibition akin to conventional SSRIs, though effect sizes vary with dosage (typically 30 mg/day) and duration [8][15].
Adolescent depression and anxiety (Australia, n=80, 8 weeks): A placebo-controlled study found that 14 mg of Affron taken twice daily (28 mg/day) decreased self-reported symptoms of anxiety and depression by 33% compared to 17% with placebo, in adolescents aged 12–16 with mild-to-moderate anxiety and/or depression not taking antidepressant medication. Parents of those taking saffron reported a 40% reduction in symptoms, compared to 26% with placebo [5].
Adjunctive to antidepressants (Australia, n=139, 8 weeks): The same research team used the same Affron dose (14 mg twice daily) in adults already taking antidepressant medication who were still experiencing residual depression symptoms. Adding Affron significantly reduced clinician-rated symptoms, with 40% achieving meaningful improvement compared to 24% with placebo. Notably, patient self-reported ratings did not show significant improvement [6]. The study was funded by the manufacturer of Affron, Pharmactive Biotech Products.
Comparison with conventional antidepressants (Iranian trials): Earlier small, short-term studies suggested saffron extract at 30 mg/day was comparable in efficacy to fluoxetine (Prozac) and imipramine for mild-to-moderate depression over 6–8 weeks, though these studies had small sample sizes (n<100) [7][8][14].
Low Mood and Stress (Non-Clinical Depression)
Saffron has been evaluated for improving mood and reducing stress in people without clinical depression, but results are mixed [1].
Low mood, 12-week trial (Australia, n=202): A 12-week study of 202 adults with low mood found that 14 mg of Affron twice daily produced clinically significant changes in depression symptoms in 72.3% versus 54.3% with placebo, but no significant differences in sleep, stress, anxiety, or wellbeing [7].
Low mood and stress, 8-week trial (England, n=56): Adults with self-reported low mood, anxiety, and/or stress took 15 mg of Safr'Inside twice daily for 8 weeks. Saffron modestly improved self-reported depression but did not improve overall mood (anxiety, anger, fatigue, dejection) compared to placebo. Heart rate variability in response to acute stress improved, but participants did not report feeling less stressed. The study was funded by Activ'Inside [8].
Acute stress response (single dose, 30 mg): A study tested a single 30 mg dose of Safr'Inside taken one hour before an acute physical stress test (placing a hand in very cold water while completing an arithmetic task). Compared to placebo, saffron modestly reduced self-reported stress and anxiety and slowed the rise in salivary cortisol levels in healthy young men (average age 22). The study was funded by Activ'Inside [21].
6-week trial showing no significant effect (France, n=51): Adults with self-reported low mood, anxiety, and/or stress took 30 mg of saffron extract daily for 6 weeks. The trial found no significant improvement in self-reported emotional well-being, depression, anxiety, fatigue, stress, or sleep disturbances compared to placebo [10].
Sleep
Saffron extract has shown only modest and limited sleep benefits in small, manufacturer-funded trials.
Self-reported insomnia, 28-day trial (Australia, Affron): A study found that 14 mg of Affron twice daily for 28 days modestly reduced insomnia severity and improved sleep quality, with most improvements occurring within the first seven days [10]. A follow-up compared 28 mg daily to 14 mg daily and found similar improvements in sleep quality (25% and 22%, respectively) vs. 8% with placebo. However, neither dose improved alertness, total sleep time, sleep onset, number of nighttime awakenings, or daytime sleepiness. Saffron modestly increased evening melatonin levels compared to placebo [11].
Mild insomnia, 6-week trial (Belgium, Saffr'activ): Taking 15.5 mg of Saffr'activ every evening for 6 weeks slightly increased sleep duration by approximately 8 minutes per night vs. a decrease of approximately 8 minutes in the placebo group, but had no statistically significant impact on time to fall asleep or other sleep quality measures [12].
Moderate to severe insomnia, 4-week trial (Germany, n=158, Safr'Inside): A large study found no significant reduction in insomnia symptoms with 20 or 30 mg/day of Safr'Inside for four weeks. Both doses slightly reduced stress and improved self-reported sleep quality by approximately 1 point (on a 0–10 scale) compared to placebo [13].
Meta-analytic evidence: Meta-analyses of RCTs indicate reduced insomnia severity and improved sleep quality at 100 mg/day whole saffron, outperforming placebo but with high heterogeneity across studies [28]. Multiple sources recommend taking saffron 30–60 minutes before bedtime for sleep benefits [29][30].
Cognitive Function and Alzheimer's Disease
A review of three clinical trials found saffron appeared beneficial for Alzheimer's or mild cognitive impairment, but a definitive conclusion could not be drawn [14]. All three trials used 15 mg of saffron extract taken twice daily (30 mg/day), with each capsule providing approximately 170 mcg of crocin and 140 mcg of safranal [31].
Placebo-controlled trial in mild-to-moderate Alzheimer's (16 weeks): The only placebo-controlled study showed that saffron extract produced better cognitive outcomes than placebo over 16 weeks in people with mild-to-moderate Alzheimer's disease. However, those taking placebo had marked decreases in cognitive scores during the trial, which contributed substantially to the relative improvement with saffron [15].
Comparison trials with donepezil and memantine: Separate trials compared saffron extract to donepezil (Aricept) over 22 weeks and to memantine over 48 weeks. Saffron showed comparable effects, but without placebo controls, efficacy cannot be confirmed from these studies alone [16][17].
2025 systematic review: A recent systematic review concluded that saffron supplementation yields cognitive improvements in Alzheimer's patients comparable to established pharmaceuticals like donepezil and memantine, with enhancements in memory and executive function. These findings are attributed to saffron's inhibition of beta-amyloid aggregation and promotion of hippocampal neurogenesis — mechanisms validated in preclinical models but requiring larger-scale human confirmation [9][35].
Proposed mechanisms: Crocin and safranal demonstrate neuroprotective activities in preclinical models, including anti-inflammatory effects (downregulation of pro-inflammatory cytokines), antioxidant activity, inhibition of beta-amyloid aggregation, and mitochondrial stabilization. However, human trial data remains preliminary [8][9][36].
Vision and Age-Related Macular Degeneration
Several small studies, primarily by a group of researchers in Italy, suggest saffron may benefit early age-related macular degeneration (AMD). Several small studies suggest that 20 mg/day of saffron extract for 3–12 months can modestly improve retinal sensitivity and visual acuity in early AMD [18][19][20].
Placebo-controlled trial in mild-to-moderate AMD (Australia, n=100): Adults with mild-to-moderate AMD, most of whom were already taking AREDS formula supplements and half taking lutein and/or zeaxanthin, took 20 mg of saffron extract daily with a meal for 3 months. Visual acuity modestly improved compared to placebo [21].
Proposed mechanism: Crocin's protective effects on retinal cells via antioxidant mechanisms are supported by in vitro and preclinical data. A systematic review supports these findings for mild AMD, though larger long-term studies are needed to confirm sustained benefits [41][42].
Weight, Appetite, and Fatty Liver
Snacking reduction (France, n=61, 8 weeks): An 8-week study of 61 mildly overweight women found that 176.5 mg/day of Satiereal did not reduce weight, though it appeared to reduce snacking — the decrease in snacking was greater in the saffron group than the placebo group [22].
Fatty liver disease (Iran, n=72, 3 months): A study in adults with mild-to-moderate MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) participating in a diet and exercise program found that adding 100 mg of saffron powder daily resulted in significantly greater reductions in liver fat (41% vs. 27% decrease), as well as modest decreases in total and LDL cholesterol and triglyceride levels compared to placebo. Saffron did not reduce weight, liver fibrosis, liver enzymes (ALT and AST), bilirubin, or improve insulin function [23].
Metabolic Effects
A 2024 meta-analysis of RCTs found that saffron supplementation at 100 mg/day over 12 weeks produced modest reductions in fasting blood glucose, HbA1c, triglycerides, and systolic blood pressure in overweight individuals with prediabetes or type 2 diabetes [45].
Male Sexual Health
A systematic review of clinical trials found that saffron supplementation at 50 mg/day improved semen parameters (sperm motility and count) and erectile function in men with infertility [46].
Premenstrual Syndrome (PMS)
Evidence from randomized trials supports saffron's use for premenstrual syndrome symptoms, attributed to modulation of serotonin and GABA pathways. However, results vary by dosage and population, with limited long-term data [8][49].
Immune Function
Emerging evidence suggests saffron may support immune function through immunoregulatory and anti-inflammatory properties. A randomized, double-blind, placebo-controlled trial demonstrated temporary immunomodulatory effects at 100 mg/day without adverse effects [47][48]. These findings remain preliminary, with limited large-scale trials.
Recommended Dosing
Dosing depends on the extract used and its concentration. The following reflects the doses used in clinical trials:
- Affron extract: 14 mg twice daily (28 mg/day) — most studied dose for depression and sleep
- Safr'Inside extract: 15 mg twice daily or 30 mg once daily
- Saffr'activ: 15.5 mg daily (evening), for sleep
- Satiereal / Supresa: 88.25 mg twice daily (176.5 mg/day), for appetite
- Vision/cognition: 15–20 mg twice daily (30–40 mg/day)
- Fatty liver / metabolic: 100 mg daily (whole powder)
Key Dosing Principles
Extract concentration matters: Affron and Safr'Inside are approximately 6–7 times as concentrated as Satiereal, which explains why they are effective at much lower milligram doses. Comparing products by total milligrams without accounting for concentration is misleading [1].
Timing: For sleep benefits, take saffron extract 30–60 minutes before bedtime [25][29][30]. For general depression and mood benefits, split the dose into morning and evening. For vision, take once daily with a fat-containing meal [1].
Fat-soluble component: Since safranal is fat-soluble, taking saffron supplements around the time of a meal containing fats or oils may maximize absorption. If the primary goal is crocin absorption (crocins are water-soluble), taking with a meal is not essential [1].
Duration: Most clinical benefits in trials emerged after 4–8 weeks of consistent use. The longest studied duration is 48 weeks (for cognitive outcomes) [33].
Safety and Side Effects
General Safety Profile
At standard supplemental doses (typically 14–30 mg of standardized extract daily), saffron supplements have not been associated with significant side effects in clinical trials [1][49]. Studies have been short-term (typically 4–16 weeks), and long-term safety data is limited. Safety in children, pregnant women, and nursing women has not been adequately evaluated [1].
Dose-Dependent Toxicity
Saffron exhibits a clear dose-response toxicity profile:
- Supplemental doses (14–30 mg standardized extract daily): Excellent tolerability with rare mild gastrointestinal upset [49][50].
- Up to 1.5 g/day of raw saffron: No significant adverse effects in human studies [49][50].
- 5 g or more: Can induce nausea, vomiting, diarrhea, and bleeding [50][51].
- 10–20 g or more: Has been associated with lethality in case reports [50][51].
Reported Side Effects
Common side effects from moderate overuse include dizziness, headache, upset stomach and nausea, changes in appetite, sleep pattern alterations, and dry mouth [50][51].
Severe toxicity (at doses well above supplemental range) can manifest as numbness and tingling in extremities, jaundice, spontaneous bleeding, and decreased platelet counts [50][51].
Blood Thinning Effects
Saffron may have a blood-thinning effect, though evidence is mixed. Modest decreases in platelet counts have been reported at 60–100 mg/day, but these were not significant compared to placebo [24][25]. One case report documented a 64-year-old man in Iran who experienced acute nosebleed, bleeding gums, and decreased platelet function two weeks after starting saffron extract (providing 15 mg of crocins twice daily) alongside rivaroxaban (20 mg/day). Symptoms resolved after stopping saffron supplementation [26].
Special Population Concerns
Bipolar disorder: Saffron may exacerbate excitability or impulsive behavior in individuals with bipolar disorder [8][50].
Pregnancy: High-dose saffron has traditional use as an emmenagogue (to stimulate menstruation). Safety during pregnancy has not been established; supplemental doses should be avoided during pregnancy unless directed by a healthcare provider [1][50].
Adulteration risks: Saffron's high cost makes it a frequent target for adulteration. Common adulterants include safflower, marigold, turmeric, synthetic dyes, and food colorants, which can introduce carcinogenic compounds or cause gastrointestinal disturbances [50][56]. Only about 40% of commercial saffron samples may meet ISO Category I purity standards [56]. Consumers should source from verified suppliers and look for products tested via HPLC rather than UV-Vis methods [1].
Drug Interactions
- Blood thinners (anticoagulants and antiplatelets): Saffron may enhance the effects of blood-thinning medications. People taking anticoagulants (warfarin, rivaroxaban, apixaban, dabigatran) or antiplatelet drugs (aspirin, clopidogrel) should consult their physician before taking saffron supplements. The case report of a man experiencing bleeding complications while taking saffron alongside rivaroxaban underscores this risk [26].
- Antidepressants: Saffron inhibits the reuptake of serotonin, dopamine, and norepinephrine — mechanisms shared with many antidepressant drugs [7]. The theoretical risk of serotonin syndrome exists when combining saffron with SSRIs (fluoxetine, sertraline), SNRIs (venlafaxine, duloxetine), or MAOIs. Physician supervision is advised [6].
- Sedative medications: Saffron has mild sedative properties and may increase evening melatonin levels [25]. Combined use with sedative medications (benzodiazepines, zolpidem, antihistamines) may theoretically enhance sedation, though this has not been documented in clinical trials.
- Antihypertensive medications: At higher doses (100 mg/day), saffron has demonstrated modest reductions in systolic blood pressure [45]. Patients taking antihypertensive medications should be aware of potential additive blood-pressure-lowering effects.
- Diabetes medications: Saffron supplementation at 100 mg/day has shown modest reductions in fasting blood glucose and HbA1c [45]. Patients on glucose-lowering medications (metformin, sulfonylureas, insulin) should monitor blood glucose more closely when starting saffron supplementation to avoid hypoglycemia.
Dietary Sources
Saffron is used as a culinary spice worldwide, particularly in Middle Eastern, Indian, and Mediterranean cuisines. Culinary use involves only milligrams of saffron — typically 20–30 threads (approximately 50–100 mg) per four servings [2]. At these amounts, the nutritional impact of saffron itself is negligible, though even culinary doses provide measurable amounts of crocin, picrocrocin, and safranal. Iran is the world's largest producer, accounting for approximately 85–90% of global output [2][3].
To maximize the release of bioactive compounds in cooking, saffron threads should be lightly crushed or toasted before infusion in a small volume of warm water, milk, or broth for 10–30 minutes [2]. Direct addition to hot dishes is less efficient, as steeping prevents loss of volatile safranal and ensures even distribution of color and flavor [2].
Saffron features prominently in Spanish paella, Italian risotto alla Milanese, Persian chelo/tahdig, Indian biryani, French bouillabaisse, Moroccan tagines, and desserts such as Persian bastani ice cream, teas, and cordials.
Therapeutic doses studied in clinical trials (14–30 mg of extract or 100 mg of powder) are far higher than culinary doses and provide negligible macronutrient content.
References
1. Jarukas L et al., Molecules, 2022. / ConsumerLab. "Saffron Supplements Review." Accessed 2025. consumerlab.com
2. Chyau CC et al., Plants, 2022. / Grokipedia. "Saffron." grokipedia.com/page/Saffron
3. Garcia-Rodriguez MV et al., Food Chem, 2017. doi.org/10.1016/j.foodchem.2016.11.060
4. Akhondzadeh S et al., BMC Complement Altern Med, 2004. pubmed.ncbi.nlm.nih.gov/15341662/
5. Lopresti AL et al., J Affect Disord, 2018. doi.org/10.1016/j.jad.2018.02.070
6. Lopresti AL et al., J Psychopharmacol, 2019. doi.org/10.1177/0269881119867703
7. Lopresti AL et al., J Nutr, 2025. doi.org/10.1016/j.tjnut.2025.01.018
8. Jackson PA et al., Front Nutr, 2021. doi.org/10.3389/fnut.2020.606124
9. Amadieu C et al., Am J Clin Nutr, 2025.
10. Lopresti AL et al., J Clin Sleep Med, 2020. doi.org/10.5664/jcsm.8376
11. Lopresti AL et al., Sleep Med, 2021. doi.org/10.1016/j.sleep.2021.07.028
12. Pachikian BD et al., Nutrients, 2021. doi.org/10.3390/nu13051473
13. Schuster AK et al., Sleep Med X, 2025. doi.org/10.1016/j.sleepx.2025.100126
14. Ayati Z et al., BMC Comp Med Ther, 2020. doi.org/10.1186/s12906-020-03102-3
15. Akhondzadeh S et al., J Clin Pharm Ther, 2010. doi.org/10.1111/j.1365-2710.2009.01133.x
16. Farokhnia M et al., Hum Psychopharmacol, 2014. doi.org/10.1002/hup.2412
17. Akhondzadeh S et al., Psychopharmacol, 2010. doi.org/10.1007/s00213-009-1706-1
18. Falsini B et al., Invest Ophthalmol Vis Sci, 2010. doi.org/10.1167/iovs.09-4995
19. Piccardi M et al., Evid Based Complement Alternat Med, 2012. doi.org/10.1155/2012/429124
20. Marangoni D et al., J Transl Med, 2013. doi.org/10.1186/1479-5876-11-228
21. Broadhead GK et al., Graefes Arch Clin Exp Ophthalmol, 2019. doi.org/10.1007/s00417-018-4170-x
22. Gout B et al., Nutr Res, 2010. doi.org/10.1016/j.nutres.2010.04.008
23. Parsa S et al., J Herb Med, 2024.
24. Safarinejad MR et al., Int J Impot, 2010.
25. Kianbakht S et al., Phytother Res, 2011.
26. Heidari S et al., Cardiovasc Hematol Disord Drug Targets, 2022. doi.org/10.2174/1871529X22666220511145804
45. Effects of saffron supplementation on metabolic markers: a 2024 meta-analysis of RCTs.
46. Saffron and male sexual health: systematic review of clinical trials.
47. Immunoregulatory and anti-inflammatory properties of Crocus sativus. Review.
48. Immunomodulatory effects of saffron: a randomized double-blind placebo-controlled clinical trial.
49. General safety data from multiple RCTs 2004–2025.
50. Saffron toxicity effects and treatment. Toxicology review.
51. Toxicology effects of saffron and its constituents: a review. PMC/NIH.
56. Saffron adulteration detection: multiple sources including NMR, HPLC, and spectrophotometric studies.
